Norstella
Citeline Podcasts
Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.
Be sure to visit the podcast's website and support the creator: www.citeline.com
Where to listen?
Podcasts in the app Replaio Radio Coming soonPodcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts
Episodes
전 세계 비만 치료제 임상시험 건 수, 미국이 가장 높아…한국은 9위 (Korean-language podcast) 11.01.2024 3:35
Join Jung Won Shin for this Korean-language mini podcast talking about a report from Citeline's Datamonitor Healthcare. Datamonitor Healthcare의 비만치료제시장 분석리포트를 요약한 내용입니다. https://www.biomedtracker.com/reportdetail.cfm?reportid=863
Scrip's Five Must-Know Things - 10 January 2024 10.01.2024 15:36
Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: 2023 drug launch highlights; the M&A outlook for the new year; AstraZeneca’s China cell therapy acquisition; the pre-Christmas deal flow; and India at a turning point for ADCs? https://scrip.citeline.com/SC149606/Quick-Listen-Scrips-Five-MustKnow-Things
Podcast: Current trends in the biotech landscape with Chris Smyth, President, ICON Biotech Solutions 09.01.2024 16:52
Listen as Chris Smyth, President, ICON Biotech Solutions discusses current trends in the biotech landscape, and predictions for future innovation, regulation and globalisation in this space. Recorded on Wednesday 15th November.
China Biotech Podcast - January 2024 (Chinese-language) 09.01.2024 29:56
One week into 2024, there have already been multiple deals between Chinese innovative drug developers and multinational and the significant acquisition of GracellBio by AstraZeneca. Brian Yang and Dexter Yan invite guest speaker Liu Liu to discuss reasons behind the particularly active deal-making scene in the China biotech sector. https://scrip.citeline.com/SC149598/Chinese-Language-Podcast--AZMN...
Cardio Conversations: AVS Cracks Calcium With Novel Pressure Wave Balloon 05.01.2024 27:03
In this edition of Cardio Conversations, Medtech Insight editor Reed Miller talked to Robert Chisena, the co-founder and CTO of AVS. He talked about the company's novel interventional technology for calcified peripheral arterial disease and how the company came together during the pandemic. Further Reading https://medtech.citeline.com/MT148128/Shockwave-Begins-First-All-Female-Study-Of-Coronary-In...
Drug Fix: Looking Back And Looking Ahead: Key US and EU Legislation 05.01.2024 36:57
Pink Sheet reporter and editors discuss key US and EU legislation that impacted 2023 and how it also could affect 2024, including EU legislative reform (:56), US Medicare drug price negotiations (14:43), and the US Food and Drug Administration user fee reauthorization (30:57). More On These Topics From The Pink Sheet European Commission Explains Impact Of EU Pharma Review On SMEs & Non-Profit Enti...
Unlock the Future of Cancer Detection with Dr Charles P. Vega, MD, FAAFP: Listen Now! 03.01.2024 11:23
Join us for an insightful Q&A session with Dr. Vega, where we delve into the groundbreaking world of Multi-Cancer Early Detection (MCED) and the future of cancer detection.
The Challenges of Rare Neurological Disease Drug Development 22.12.2023 27:55
In this episode, In Vivo speaks to Bruce Leuchter, CEO of Neurvati Neurosciences, about ways clinical drug development in rare neurologic diseases is being held back and what can be done to make the process more efficient and successful.
【3分で解説 世界のファーマ】第15回 治験に被験者の「多様性」を 米国の課題 (Japanese-language podcast) 22.12.2023 3:17
世界の製薬ビジネスを伝える「Scrip」と、各国で変化する製薬関連の規制に特化した「Pink Sheet」。普段は英語で発信する2つのオンラインメディアから、今注目の話題を日本語で短くまとめてお届けします。 今回取り上げた記事はこちら 「Clinical Trial Diversity Plans: Early Oncology Experience Shows More Work Needed, US FDA Says(邦題意訳:FDA、被験者の多様性を義務化へ がん治験では課題も)」 https://pink.citel...
Medtech Connect Episode 11: A Look Back At 2023 20.12.2023 17:41
In this episode, Medtech Insight regulatory reporter Hannah Daniel speaks to King & Spalding’s Eric Henry about the year’s most influential digital health regulations in the US and EU, and what we may have missed in all the excitement.
Biopharma’s Must-Know 2023-4 Catalysts 20.12.2023 6:36
In this podcast Scrip looks at the some upcoming clinical catalysts for biopharma, judged by the size of the sales forecasts at stake. Companies including Sanofi, Cytokinetics, Corcept and Inventiva stand to gain – or lose.
Scrip’s Five Must-Know Things – 19 December 2023 19.12.2023 15:35
Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: first ever gene editing FDA nod; US FTC ruffles pharma’s feathers; AstraZeneca pays to play in RSV; Syndax leukemia drug makes splash at ASH; BMS bets big on Chinese ADC. https://scrip.citeline.com/SC149527/Quick-Listen-Scrips-Five-MustKnow-Things
Drug Fix: Taking A Look Back, And Forward, With US FDA’s Project Orbis 15.12.2023 23:30
Pink Sheet reporters and editors in the US and Europe consider the growth and impact of Project Orbis after a year in which two major regulators joined the program, but several countries did not keep up with the US approval pace. More On These Topics From The Pink Sheet Project Orbis 2023: FDA Approves Six New Cancer Drugs, But Partner Nations Lag Behind: https://pink.citeline.com/PS149452/Project...
China Biotech Podcast - December 2023 (Chinese-language) 14.12.2023 32:58
Brian Yang and Dexter Yan discuss Biokin/BMS's ADC deal, WuXi Biologics' share price drop, BlissBio's recent developments and Pfizer's divestment of Prevenar 13 commercial rights in China to a Chinese local partner. https://scrip.citeline.com/SC149497/Chinese-Language-Podcast-BiokinBMS-Deal-Developments-At-Pfizer-BlissBio-WuXi-Biologics
Scrip’s Five Must-Know Things – 11 December 2023 11.12.2023 14:40
Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: another acquisition for AbbVie; Roche buys into the obesity market; J&J’s oral immunology push; oral incretins advance; and AstraZeneca on Chinese innovation. https://scrip.citeline.com/SC149480/Quick-Listen-Scrips-Five-MustKnow-Things
Over the Counter 7 Dec 2023: IFRA On Potential Impact Of EU's CLP Revision 07.12.2023 16:54
In this episode, HBW Insight speaks to Aurélie Perrichet, regional director, Europe at the International Fragrance Association. We discussed the implications of planned revisions to the European Commission’s Classification, Labeling and Packaging (CLP) regulation, which may re-categorize biological materials as mixtures, from their current status as substances. Perrichet also speculated how the pr...
제약업계의 생성형AI 적용 성공의 열쇠는? (Korean-language podcast) 05.12.2023 4:09
최근 제프리스 헬스케어 컨퍼런스에서 발표된 제약바이오산업의 생성형인공지능 적용사례에 대한 Scrip 기사를 요약한 내용입니다. https://scrip.citeline.com/SC149412/As-Biopharma-Adopts-Generative-AI-The-People-Element-Is-Crucial-To-Success
Scrip's Five Must-Know Things - 4 December 2023 04.12.2023 16:45
Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: CAR-Ts and malignancies; comeback for GSK’s Blenrep?; Novartis’s pipeline cull; FGF21 analogs in NASH; and a call to action from the Scrip Awards Lifetime Achievement winner. https://scrip.citeline.com/SC149443/Quick-Listen-Scrips-Five-MustKnow-Things
Drug Fix: CAR-T Malignancy Reports, Background Music In DTC Ads, New No. 2 At US FDA 01.12.2023 20:38
Pink Sheet reporter and editors discuss the FDA acknowledging reports of malignancies in patients who received CAR-T cell immunotherapies (:35), the agency’s policy for using background music in direct-to-consumer advertising (7:27), and the FDA’s new incoming principal deputy commissioner (13:44). More On These Topics From The Pink Sheet CAR-T Malignancy Reports Could Temper Excitement For Use Be...
RNA And Kidneys And Diagnostics RNA, Oh My – Discussing Verici DX’s Differentiated Product Offering 27.11.2023 26:36
In this podcast, In Vivo speaks to Sara Barrington, CEO of Verici DX. During the discussion, Barrington outlines the current challenges facing patients post-transplant, why current diagnostics are inadequate, and where the overall transplant market is headed, considering the rise of home dialysis and the potential future for xenotransplants.
Scrip’s Five Must-Know Things – 27 November 2023 27.11.2023 15:02
Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: Bayer’s Phase III failure; US group seeks Japan changes; AstraZeneca winning AKT race for now; NASH developments at AASLD; and the Q3 impact of China’s corruption campaign. https://scrip.citeline.com/SC149413/Quick-Listen-Scrips-Five-MustKnow-Things
Trends In Epidemiology 23.11.2023 24:59
Datamonitor Healthcare’s Epidemiology team (Ridwaan Ibrahim, Lucia Rodriguez-Garcia, Maya Trivedy, and Asma Ali) discuss the current trends in epidemiology throughout the world, and how epidemiology data is being used to support drug discovery and improve health outcomes. Topics discussed include epidemiology methodologies, Alzheimer’s Disease, non-communicable diseases in Africa, genetic epidemio...
Scrip Lifetime Achievement Award 2023: Jeremy Levin’s Acceptance Speech 22.11.2023 9:20
In accepting Scrip’s Lifetime Achievement Award, Ovid Therapeutics’ CEO called on pharma to show responsible leadership and live up to its potential to do good for society.
China Biotech Podcast (Chinese language) - November 2023 21.11.2023 32:04
Brian Yang and Dexter Yan discuss the FDA approval of Chinese PD-1, Sanofi BioMap AI deal, Third quarter earnings and Biden-Xi Summit and US-China regulatory dialogue.
Discussing The Potentials Of And Challenges For Digital Therapeutics 21.11.2023 31:51
In this podcast, Medtech Insight speaks to Andy Molnar, CEO of the digital therapeutics alliance; Joel Morse, CEO and co-founder of Curavit and Owen McCarthy, CEO and co-founder of MedRhythyms. The trio discuss the current situation surrounding digital therapeutics, and where they believe they are headed in the coming years.
Similar podcasts
Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.